235 related articles for article (PubMed ID: 29710505)
1. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.
Soheilifar MH; Taheri RA; Zolfaghari Emameh R; Moshtaghian A; Kooshki H; Motie MR
Biomed Pharmacother; 2018 Jul; 103():889-896. PubMed ID: 29710505
[TBL] [Abstract][Full Text] [Related]
2. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
Paoluzzi L; Maki RG
JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.
Conde N; Cruz O; Albert A; Mora J
Pediatr Blood Cancer; 2011 Dec; 57(6):1071-3. PubMed ID: 21744483
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
Brahmi M; Vanacker H; Dufresne A
Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
7. Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma.
Castelli C; Tazzari M; Negri T; Vergani B; Rivoltini L; Stacchiotti S; Pilotti S
J Transl Med; 2013 Sep; 11():237. PubMed ID: 24074204
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
10. Advanced alveolar soft part sarcoma responds to apatinib.
Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma.
Lazar AJ; Das P; Tuvin D; Korchin B; Zhu Q; Jin Z; Warneke CL; Zhang PS; Hernandez V; Lopez-Terrada D; Pisters PW; Pollock RE; Lev D
Clin Cancer Res; 2007 Dec; 13(24):7314-21. PubMed ID: 18094412
[TBL] [Abstract][Full Text] [Related]
12. Mimicking angiogenic microenvironment of alveolar soft-part sarcoma in a microfluidic coculture vasculature chip.
Chuaychob S; Lyu R; Tanaka M; Haginiwa A; Kitada A; Nakamura T; Yokokawa R
Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2312472121. PubMed ID: 38502703
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
Ghose A; Tariq Z; Veltri S
Am J Ther; 2012 Jan; 19(1):e56-8. PubMed ID: 20634674
[TBL] [Abstract][Full Text] [Related]
14. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of alveolar soft part sarcoma.
O'Sullivan Coyne G; Naqash AR; Sankaran H; Chen AP
Curr Probl Cancer; 2021 Aug; 45(4):100775. PubMed ID: 34284873
[TBL] [Abstract][Full Text] [Related]
16. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
Zhao J; Yang Y
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
[TBL] [Abstract][Full Text] [Related]
17. Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.
Fujiwara T; Nakata E; Kunisada T; Ozaki T; Kawai A
BMC Cancer; 2022 Aug; 22(1):891. PubMed ID: 35971085
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery as a primary treatment for metastatic skull base alveolar soft part sarcoma: a case report.
Shinya Y; Hasegawa H; Kawashima M; Shin M; Takahashi W; Kobayashi H; Saito N
Acta Neurochir (Wien); 2021 Feb; 163(2):351-355. PubMed ID: 32686069
[TBL] [Abstract][Full Text] [Related]
19. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.
Pink D; Bertz-Lepel J; Busemann C; Bitz U; Reichardt P
Onkologie; 2012; 35(5):249-52. PubMed ID: 22868503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
